Jasper Therapeutics, Inc. (JSPR): Nasdaq/NYSE listing notice — Jasper Therapeutics receives Nasdaq bid price deficiency notice; must regain compliance by Apr 15, 2024

Jasper Therapeutics, Inc.

Notice from Nasdaq: common stock bid price below $1.00 for 30 consecutive business days.
Company has 180 days, until April 15, 2024, to regain compliance with Rule 5550(a)(2).
If bid price closes at $1.00 or more for ten consecutive days, Nasdaq will confirm compliance.
Company may consider a reverse stock split to cure deficiency; no assurance of regaining compliance.
Trading of common stock (JSPR) and warrants (JSPRW) continues on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Jasper Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(ii)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)(ii)

Exact text from the filing

October 18, 2023, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A)(ii), the Company has been provided an initial period of 180 calendar days, or until April 15, 2024, to regain compliance.

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001013762-23-005230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.